// ============================================================
// TERRAIN — Competitor Database
// lib/data/competitor-database.ts
//
// Static database of competitive assets organized by indication.
// Each record represents a drug/biologic in development or on market.
// Sources: ClinicalTrials.gov, FDA, SEC filings, company pipelines,
// Evaluate Pharma, BioCentury (2020-2025)
// ============================================================

import type { ClinicalPhase } from '@/types';

// ────────────────────────────────────────────────────────────
// COMPETITOR RECORD TYPE
// ────────────────────────────────────────────────────────────

export interface CompetitorRecord {
  asset_name: string;
  generic_name?: string;
  company: string;
  indication: string;                    // Normalized indication name
  indication_specifics: string;          // Exact label or trial population
  mechanism: string;                     // Human-readable mechanism
  mechanism_category: string;            // Normalized category for grouping
  molecular_target?: string;
  phase: ClinicalPhase;
  primary_endpoint?: string;
  key_data?: string;
  line_of_therapy?: string;              // "1L", "2L", "2L+", "maintenance", "adjuvant", "neoadjuvant"
  partner?: string;
  nct_ids?: string[];
  first_in_class: boolean;
  orphan_drug: boolean;
  has_biomarker_selection: boolean;
  strengths: string[];
  weaknesses: string[];
  source: string;
  last_updated: string;
}

// ────────────────────────────────────────────────────────────
// COMPETITOR DATA
// ────────────────────────────────────────────────────────────

export const COMPETITOR_DATABASE: CompetitorRecord[] = [

  // ══════════════════════════════════════════════════════════
  // NON-SMALL CELL LUNG CANCER (NSCLC)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L NSCLC, PD-L1 TPS >= 1%, monotherapy or + chemo',
    mechanism: 'PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'KEYNOTE-024/189: OS benefit in 1L NSCLC with PD-L1 >= 50% (HR 0.63) and + chemo (HR 0.49)',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Dominant 1L market share', 'Broadest label across tumor types', 'Extensive combination data'],
    weaknesses: ['LOE approaching 2028', 'Diminishing PFS/OS gains in unselected populations'],
    source: 'FDA label; KEYNOTE trials; Merck 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Opdivo',
    generic_name: 'nivolumab',
    company: 'Bristol-Myers Squibb',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L NSCLC + ipilimumab + chemo or monotherapy 2L+',
    mechanism: 'PD-1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'CheckMate-9LA: 1L NSCLC OS with nivo + ipi + chemo (HR 0.73 at 4-year follow-up)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Strong brand', 'IO-IO combination strategy', 'Long-term survival data'],
    weaknesses: ['Trailing Keytruda in NSCLC market share', 'Complex dosing with ipilimumab'],
    source: 'FDA label; CheckMate trials; BMS 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tagrisso',
    generic_name: 'osimertinib',
    company: 'AstraZeneca',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L EGFR-mutated (ex19del, L858R) NSCLC',
    mechanism: '3rd-gen EGFR TKI',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'EGFR',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'FLAURA: 1L EGFR+ NSCLC PFS 18.9 vs 10.2 mo (HR 0.46); FLAURA2: + chemo PFS 25.5 mo',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Gold standard in EGFR+ NSCLC', 'CNS penetration', 'Adjuvant indication'],
    weaknesses: ['Resistance mutations (C797S)', 'Limited to EGFR-mutated population'],
    source: 'FDA label; FLAURA/FLAURA2 trials; AZ 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lumakras',
    generic_name: 'sotorasib',
    company: 'Amgen',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '2L+ KRAS G12C-mutated NSCLC after prior systemic therapy',
    mechanism: 'KRAS G12C inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'KRAS G12C',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'CodeBreaK 200: ORR 28.1% vs 13.2% docetaxel; PFS 5.6 vs 4.5 mo (HR 0.66)',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First-in-class KRAS G12C', 'Oral dosing', 'Biomarker-selected'],
    weaknesses: ['Modest ORR', 'No OS benefit demonstrated', 'Narrow patient segment (~13% of NSCLC)'],
    source: 'FDA label; CodeBreaK trials; Amgen 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Krazati',
    generic_name: 'adagrasib',
    company: 'Mirati/BMS',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '2L+ KRAS G12C-mutated NSCLC',
    mechanism: 'KRAS G12C inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'KRAS G12C',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'KRYSTAL-1: ORR 42.9% in 2L NSCLC; CNS activity demonstrated; KRYSTAL-7 1L ongoing',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Higher ORR than sotorasib', 'CNS penetration', 'Longer half-life'],
    weaknesses: ['GI/hepatic toxicity signal', 'Accelerated approval — confirmatory trial needed'],
    source: 'FDA label; KRYSTAL trials; Mirati/BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Alecensa',
    generic_name: 'alectinib',
    company: 'Roche/Genentech',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L ALK-positive NSCLC',
    mechanism: 'ALK inhibitor (2nd-gen)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'ALK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ALEX: PFS 34.8 vs 10.9 mo vs crizotinib (HR 0.43); CNS efficacy 81% ORR',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Superior PFS in ALK+', 'Excellent CNS activity', 'Well-tolerated'],
    weaknesses: ['Limited to ALK+ population (~5% of NSCLC)', 'Resistance develops'],
    source: 'FDA label; ALEX trial; Roche 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lorbrena',
    generic_name: 'lorlatinib',
    company: 'Pfizer',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L ALK-positive NSCLC',
    mechanism: '3rd-gen ALK/ROS1 inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'ALK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'CROWN: 1L ALK+ PFS NR vs 9.3 mo crizotinib at 3 yr (HR 0.27); 5-yr PFS 60%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Best-in-class PFS in ALK+', 'Active against most ALK resistance mutations', 'CNS penetration'],
    weaknesses: ['CNS side effects (cognitive, mood)', 'Hyperlipidemia', 'Small addressable population'],
    source: 'FDA label; CROWN trial; Pfizer 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Imfinzi',
    generic_name: 'durvalumab',
    company: 'AstraZeneca',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: 'Stage III unresectable NSCLC after CRT; 1L extensive-stage SCLC',
    mechanism: 'PD-L1 inhibitor',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'PACIFIC: Stage III NSCLC PFS 16.8 vs 5.6 mo (HR 0.52); 5-yr OS 42.9%',
    line_of_therapy: 'maintenance',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Dominant in Stage III consolidation', 'Long-term survival data', 'Expanding to biliary/bladder'],
    weaknesses: ['Limited 1L metastatic NSCLC share', 'Competition from Keytruda combinations'],
    source: 'FDA label; PACIFIC trial; AZ 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rybrevant',
    generic_name: 'amivantamab',
    company: 'Johnson & Johnson',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: 'EGFR exon 20 insertion NSCLC; 1L with lazertinib',
    mechanism: 'EGFR-MET bispecific antibody',
    mechanism_category: 'bispecific',
    molecular_target: 'EGFR/MET',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'MARIPOSA: 1L EGFR+ with lazertinib PFS 23.7 vs 16.6 mo vs Tagrisso (HR 0.70)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First bispecific in NSCLC', 'Superiority vs Tagrisso in combination', 'Novel mechanism for EGFR ex20ins'],
    weaknesses: ['IV administration', 'Infusion reactions', 'VTE risk'],
    source: 'FDA label; MARIPOSA/CHRYSALIS trials; J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Dato-DXd',
    generic_name: 'datopotamab deruxtecan',
    company: 'Daiichi Sankyo/AstraZeneca',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '2L+ non-squamous NSCLC after platinum-based chemo + IO',
    mechanism: 'ADC (Trop-2)',
    mechanism_category: 'adc',
    molecular_target: 'TROP2',
    phase: 'Phase 3',
    primary_endpoint: 'OS',
    key_data: 'TROPION-Lung01: PFS 4.4 vs 3.7 mo vs docetaxel (HR 0.75); OS data immature',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Novel ADC platform in NSCLC', 'Potential 1L combinations', 'Manageable toxicity'],
    weaknesses: ['Modest PFS improvement', 'ILD/pneumonitis risk', 'No OS benefit yet'],
    source: 'TROPION-Lung01 (NCT04656652); ASCO 2024',
    last_updated: '2024-12-01',
  },
  {
    asset_name: 'Ivonescimab',
    generic_name: 'ivonescimab',
    company: 'Akeso/Summit Therapeutics',
    indication: 'Non-Small Cell Lung Cancer',
    indication_specifics: '1L PD-L1+ NSCLC monotherapy',
    mechanism: 'PD-1/VEGF bispecific antibody',
    mechanism_category: 'bispecific',
    molecular_target: 'PD-1/VEGF',
    phase: 'Phase 3',
    primary_endpoint: 'PFS',
    key_data: 'HARMONi-2: 1L PD-L1+ NSCLC PFS 11.1 vs 7.1 mo vs pembrolizumab (HR 0.51)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Head-to-head superiority vs Keytruda', 'Novel dual mechanism', 'Anti-angiogenic IO combination in single molecule'],
    weaknesses: ['China-centric data (generalizability)', 'US confirmatory trials ongoing', 'Manufacturing complexity'],
    source: 'HARMONi-2 (NCT05499390); WCLC 2024',
    last_updated: '2024-11-01',
  },

  // ══════════════════════════════════════════════════════════
  // BREAST CANCER
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Enhertu',
    generic_name: 'trastuzumab deruxtecan',
    company: 'Daiichi Sankyo/AstraZeneca',
    indication: 'Breast Cancer',
    indication_specifics: 'HER2+ and HER2-low metastatic breast cancer',
    mechanism: 'ADC (HER2)',
    mechanism_category: 'adc',
    molecular_target: 'HER2',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'DESTINY-Breast03: HER2+ PFS 28.8 vs 6.8 mo vs T-DM1; DESTINY-Breast04: HER2-low PFS 9.9 vs 5.1 mo',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Paradigm-shifting HER2-low activity', 'Deep responses', 'Expanding indications'],
    weaknesses: ['ILD/pneumonitis risk', 'IV administration', 'High cost'],
    source: 'FDA label; DESTINY-Breast trials; Daiichi Sankyo 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Trodelvy',
    generic_name: 'sacituzumab govitecan',
    company: 'Gilead',
    indication: 'Breast Cancer',
    indication_specifics: 'TNBC 2L+; HR+/HER2- after endocrine + 2 chemos',
    mechanism: 'ADC (Trop-2)',
    mechanism_category: 'adc',
    molecular_target: 'TROP2',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ASCENT: TNBC PFS 5.6 vs 1.7 mo (HR 0.41); TROPiCS-02: HR+ PFS 5.5 vs 4.0 mo (HR 0.66)',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First Trop-2 ADC approved', 'Activity in TNBC and HR+', 'Established safety profile'],
    weaknesses: ['Neutropenia/diarrhea', 'Modest PFS gains in HR+', 'Competition from Enhertu'],
    source: 'FDA label; ASCENT/TROPiCS-02 trials; Gilead 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Verzenio',
    generic_name: 'abemaciclib',
    company: 'Eli Lilly',
    indication: 'Breast Cancer',
    indication_specifics: 'HR+/HER2- early and metastatic breast cancer',
    mechanism: 'CDK4/6 inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'CDK4/6',
    phase: 'Approved',
    primary_endpoint: 'iDFS',
    key_data: 'monarchE: adjuvant HR+/HER2- high-risk iDFS HR 0.664; 5-yr absolute benefit ~7.6%',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Only CDK4/6i with adjuvant approval', 'Single-agent activity', 'Strong clinical franchise'],
    weaknesses: ['Diarrhea burden', 'Competition from Ibrance/Kisqali', 'Ki-67 biomarker debate'],
    source: 'FDA label; monarchE trial; Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Kisqali',
    generic_name: 'ribociclib',
    company: 'Novartis',
    indication: 'Breast Cancer',
    indication_specifics: 'HR+/HER2- metastatic breast cancer + aromatase inhibitor or fulvestrant',
    mechanism: 'CDK4/6 inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'CDK4/6',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'MONALEESA-2/3/7: OS benefit across subgroups; only CDK4/6i with OS benefit in 1L pre/peri-menopausal',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['OS benefit demonstrated', 'Broad population coverage', 'NATALEE adjuvant data emerging'],
    weaknesses: ['QTc prolongation monitoring', 'Neutropenia management', 'Ibrance generic erosion pulling class pricing down'],
    source: 'FDA label; MONALEESA trials; Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'ARV-471',
    generic_name: 'vepdegestrant',
    company: 'Arvinas/Pfizer',
    indication: 'Breast Cancer',
    indication_specifics: 'HR+/HER2- metastatic breast cancer, post-CDK4/6i',
    mechanism: 'Oral ER PROTAC degrader',
    mechanism_category: 'degrader',
    molecular_target: 'Estrogen Receptor',
    phase: 'Phase 3',
    primary_endpoint: 'PFS',
    key_data: 'Phase 1/2: ORR 33% with palbociclib combo in CDK4/6i-pretreated patients',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First oral ER degrader (PROTACs)', 'Novel mechanism for ESR1 mutations', 'Pfizer partnership validates approach'],
    weaknesses: ['Phase 3 data pending', 'Competition from next-gen oral SERDs', 'Novel modality risk'],
    source: 'VERITAC-2 (NCT05654623); Arvinas/Pfizer 2024',
    last_updated: '2024-11-01',
  },

  // ══════════════════════════════════════════════════════════
  // MULTIPLE MYELOMA
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Darzalex Faspro',
    generic_name: 'daratumumab/hyaluronidase',
    company: 'Johnson & Johnson',
    indication: 'Multiple Myeloma',
    indication_specifics: '1L through 4L+ multiple myeloma; multiple combination regimens',
    mechanism: 'Anti-CD38 monoclonal antibody (SC)',
    mechanism_category: 'anti_cd38',
    molecular_target: 'CD38',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'MAIA: 1L NDMM PFS 61.9 vs 34.4 mo (HR 0.55); frontline backbone for most regimens',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Standard-of-care backbone', 'Broadest indications in MM', 'SC formulation convenience'],
    weaknesses: ['Class saturation with Sarclisa', 'High utilization means limited growth', 'Resistance in late lines'],
    source: 'FDA label; MAIA trial; J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tecvayli',
    generic_name: 'teclistamab',
    company: 'Johnson & Johnson',
    indication: 'Multiple Myeloma',
    indication_specifics: 'R/R MM after >= 4 prior lines including PI, IMiD, and anti-CD38',
    mechanism: 'BCMAxCD3 bispecific',
    mechanism_category: 'bispecific',
    molecular_target: 'BCMA',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'MajesTEC-1: ORR 63%; CR rate 39.4% in heavily pretreated MM; 18.4 mo median DOR',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Off-the-shelf bispecific (no manufacturing delay)', 'Deep responses in late-line', 'Moving to earlier lines'],
    weaknesses: ['CRS and ICANS risk', 'Infections from T-cell engagement', 'Step-up dosing required'],
    source: 'FDA label; MajesTEC-1 trial; J&J 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Carvykti',
    generic_name: 'ciltacabtagene autoleucel',
    company: 'Johnson & Johnson/Legend Biotech',
    indication: 'Multiple Myeloma',
    indication_specifics: 'R/R MM after >= 1 prior line (CARTITUDE-4); 4L+ (initial)',
    mechanism: 'BCMA-directed CAR-T',
    mechanism_category: 'car_t',
    molecular_target: 'BCMA',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'CARTITUDE-4: 2L+ PFS 15-mo rate 76% vs 49% (HR 0.26); CARTITUDE-1: ORR 98%',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Deepest responses in MM history', 'MRD negativity > 60%', 'Moving to earlier lines'],
    weaknesses: ['Manufacturing vein-to-vein time', 'CRS/ICANS/parkinsonism', 'Limited manufacturing capacity'],
    source: 'FDA label; CARTITUDE trials; J&J/Legend 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Abecma',
    generic_name: 'idecabtagene vicleucel',
    company: 'Bristol-Myers Squibb/2seventy bio',
    indication: 'Multiple Myeloma',
    indication_specifics: 'R/R MM after >= 2 prior lines (KarMMa-3)',
    mechanism: 'BCMA-directed CAR-T',
    mechanism_category: 'car_t',
    molecular_target: 'BCMA',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'KarMMa-3: 2L+ PFS 13.3 vs 4.4 mo (HR 0.49); ORR 71%',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First BCMA CAR-T approved', 'Established manufacturing', 'PFS benefit in earlier line'],
    weaknesses: ['Inferior to Carvykti in response depth', 'Shorter DOR', 'BMS/2seventy manufacturing challenges'],
    source: 'FDA label; KarMMa trials; BMS 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'FOLFIRINOX',
    company: 'Generic regimen',
    indication: 'Pancreatic Ductal Adenocarcinoma',
    indication_specifics: '1L metastatic PDAC, fit patients',
    mechanism: 'Combination chemotherapy (5-FU/LV/irinotecan/oxaliplatin)',
    mechanism_category: 'chemotherapy',
    molecular_target: undefined,
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'PRODIGE 4/ACCORD 11: mOS 11.1 vs 6.8 mo vs gemcitabine',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Best OS in 1L PDAC', 'Proven regimen', 'Low drug cost'],
    weaknesses: ['Severe toxicity', 'Not tolerable in many patients', 'No targeted component'],
    source: 'NCCN Guidelines; PRODIGE 4 trial',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Abraxane',
    generic_name: 'nab-paclitaxel',
    company: 'BMS (ex-Celgene)',
    indication: 'Pancreatic Ductal Adenocarcinoma',
    indication_specifics: '1L metastatic PDAC + gemcitabine',
    mechanism: 'Nanoparticle albumin-bound taxane',
    mechanism_category: 'chemotherapy',
    molecular_target: undefined,
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'MPACT: mOS 8.5 vs 6.7 mo with gem/abraxane vs gem alone',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Better tolerated than FOLFIRINOX', 'Suitable for older patients', 'Well-characterized safety'],
    weaknesses: ['Inferior efficacy vs FOLFIRINOX', 'Peripheral neuropathy', 'Patent cliff'],
    source: 'FDA label; MPACT trial; BMS 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'RAS(ON) inhibitor (MRTX1133)',
    generic_name: 'MRTX1133',
    company: 'Mirati/BMS',
    indication: 'Pancreatic Ductal Adenocarcinoma',
    indication_specifics: 'KRAS G12D-mutated PDAC',
    mechanism: 'KRAS G12D(ON) inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'KRAS G12D',
    phase: 'Phase 1/2',
    primary_endpoint: 'ORR',
    key_data: 'Phase 1: Dose-dependent tumor shrinkage in KRAS G12D+ PDAC patients',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Targets dominant KRAS mutation in PDAC (~30%)', 'First KRAS G12D inhibitor', 'Transformative potential'],
    weaknesses: ['Very early data', 'Narrow patient selection', 'Combination strategy unclear'],
    source: 'AACR 2024; NCT05737706',
    last_updated: '2024-10-01',
  },

  // ══════════════════════════════════════════════════════════
  // ACUTE MYELOID LEUKEMIA (AML)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Venclexta',
    generic_name: 'venetoclax',
    company: 'AbbVie/Roche',
    indication: 'Acute Myeloid Leukemia',
    indication_specifics: '1L AML with azacitidine in patients ineligible for intensive chemo',
    mechanism: 'BCL-2 inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'BCL-2',
    phase: 'Approved',
    primary_endpoint: 'OS',
    key_data: 'VIALE-A: mOS 14.7 vs 9.6 mo with ven/aza vs aza (HR 0.66)',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Standard-of-care in unfit AML', 'Deepest responses without intensive chemo', 'Expanding to MDS'],
    weaknesses: ['Tumor lysis syndrome risk', 'Cytopenias', 'Resistance via BCL-2 independence'],
    source: 'FDA label; VIALE-A trial; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ivosidenib',
    generic_name: 'ivosidenib',
    company: 'Servier',
    indication: 'Acute Myeloid Leukemia',
    indication_specifics: 'IDH1-mutated AML (newly diagnosed or R/R)',
    mechanism: 'IDH1 inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'IDH1',
    phase: 'Approved',
    primary_endpoint: 'ORR',
    key_data: 'AGILE: 1L IDH1+ AML CR/CRh 47.2% vs 14.9% with ivo/aza vs aza',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Biomarker-selected', 'Oral administration', 'Durable responses in IDH1+'],
    weaknesses: ['Small patient subset (~8% AML)', 'Differentiation syndrome risk', 'Competition from broader-acting agents'],
    source: 'FDA label; AGILE trial; Servier 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Revumenib',
    generic_name: 'revumenib',
    company: 'Syndax Pharmaceuticals',
    indication: 'Acute Myeloid Leukemia',
    indication_specifics: 'R/R KMT2A-rearranged AML',
    mechanism: 'Menin inhibitor',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'Menin-KMT2A',
    phase: 'Approved',
    primary_endpoint: 'CR/CRh',
    key_data: 'AUGMENT-101: CR/CRh 21.1% in R/R KMT2A-rearranged AML; MRD negativity 78% of CR',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First menin inhibitor approved', 'Novel mechanism', 'MRD negativity achievable'],
    weaknesses: ['QTc prolongation', 'Differentiation syndrome', 'Small patient population'],
    source: 'FDA label; AUGMENT-101 trial; Syndax 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Imbruvica',
    generic_name: 'ibrutinib',
    company: 'AbbVie/Johnson & Johnson',
    indication: 'Chronic Lymphocytic Leukemia',
    indication_specifics: '1L and R/R CLL; including del(17p)',
    mechanism: 'BTK inhibitor (covalent)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'RESONATE-2: PFS NR vs 15 mo at 5 yr vs chlorambucil in 1L; ALPINE inferior to zanubrutinib',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['First BTK inhibitor', 'Extensive real-world data', 'Multiple heme indications'],
    weaknesses: ['Cardiac toxicity (A-fib, HTN)', 'Off-target kinase effects', 'Losing share to 2nd-gen BTKi'],
    source: 'FDA label; RESONATE/ALPINE trials; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Brukinsa',
    generic_name: 'zanubrutinib',
    company: 'BeiGene',
    indication: 'Chronic Lymphocytic Leukemia',
    indication_specifics: '1L and R/R CLL/SLL',
    mechanism: 'BTK inhibitor (next-gen, selective)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ALPINE: PFS superior to ibrutinib in R/R CLL (HR 0.65); better cardiac safety',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Best-in-class safety vs ibrutinib', 'Head-to-head PFS superiority', 'Rapid share gain'],
    weaknesses: ['Not yet established in 1L fixed-duration', 'Neutropenia', 'Same resistance mechanism as ibrutinib'],
    source: 'FDA label; ALPINE trial; BeiGene 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Calquence',
    generic_name: 'acalabrutinib',
    company: 'AstraZeneca',
    indication: 'Chronic Lymphocytic Leukemia',
    indication_specifics: '1L and R/R CLL',
    mechanism: 'BTK inhibitor (2nd-gen, selective)',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'PFS',
    key_data: 'ELEVATE-TN: 1L PFS 87% at 4 yr with aca-obinutuzumab; ASCEND: R/R PFS superior to BR/IdR',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: ['Strong 1L data with obinutuzumab', 'Fixed-duration potential', 'Better GI tolerability'],
    weaknesses: ['Headache common', 'Losing share to zanubrutinib', 'No head-to-head vs zanubrutinib'],
    source: 'FDA label; ELEVATE-TN/ASCEND; AZ 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // ALZHEIMER'S DISEASE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Leqembi',
    generic_name: 'lecanemab',
    company: 'Eisai/Biogen',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Early AD with confirmed amyloid pathology',
    mechanism: 'Anti-amyloid beta antibody (protofibril-selective)',
    mechanism_category: 'anti_amyloid',
    molecular_target: 'Amyloid beta (protofibrils)',
    phase: 'Approved',
    primary_endpoint: 'CDR-SB',
    key_data: 'Clarity AD: CDR-SB decline -27% vs placebo at 18 mo; 59% amyloid clearance',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['First anti-amyloid with traditional approval', 'Amyloid clearance', 'IV and SC formulations'],
    weaknesses: ['ARIA-E/H risk (12.6%)', 'Modest clinical benefit debated', 'Infusion burden', 'Amyloid PET/CSF required'],
    source: 'FDA label; Clarity AD trial; Eisai 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Kisunla',
    generic_name: 'donanemab',
    company: 'Eli Lilly',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Early symptomatic AD with amyloid and tau pathology',
    mechanism: 'Anti-amyloid beta antibody (N3pG-selective)',
    mechanism_category: 'anti_amyloid',
    molecular_target: 'Amyloid beta (pyroglutamate)',
    phase: 'Approved',
    primary_endpoint: 'iADRS',
    key_data: 'TRAILBLAZER-ALZ 2: iADRS decline -35% vs placebo (low/med tau); 80% amyloid clearance → stop dosing',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['Higher magnitude benefit in low/med tau', 'Treatment completion (amyloid clearance endpoint)', 'Time-limited dosing'],
    weaknesses: ['ARIA-E/H risk', 'Tau PET stratification complex', 'Amyloid PET required', 'High drug cost'],
    source: 'FDA label; TRAILBLAZER-ALZ 2; Eli Lilly 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Remternetug',
    generic_name: 'remternetug',
    company: 'Eli Lilly',
    indication: "Alzheimer's Disease",
    indication_specifics: 'Early AD with amyloid pathology (subcutaneous)',
    mechanism: 'Anti-amyloid beta antibody (pyroglutamate + fibril)',
    mechanism_category: 'anti_amyloid',
    molecular_target: 'Amyloid beta',
    phase: 'Phase 3',
    primary_endpoint: 'CDR-SB',
    key_data: 'Phase 2: >80% amyloid clearance by 12 weeks; fastest amyloid removal observed',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: ['SC formulation', 'Fastest amyloid clearance', 'Could enable shortest treatment duration'],
    weaknesses: ['ARIA risk may be higher with rapid clearance', 'Phase 3 not yet reported', 'Behind donanemab in development'],
    source: 'NCT05463731; Eli Lilly 2024',
    last_updated: '2024-10-01',
  },

  // ══════════════════════════════════════════════════════════
  // PARKINSON'S DISEASE
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Prasinezumab',
    generic_name: 'prasinezumab',
    company: 'Roche/Prothena',
    indication: "Parkinson's Disease",
    indication_specifics: 'Early PD (disease modification)',
    mechanism: 'Anti-alpha-synuclein antibody',
    mechanism_category: 'anti_alpha_synuclein',
    molecular_target: 'Alpha-synuclein',
    phase: 'Phase 2/3',
    primary_endpoint: 'MDS-UPDRS Part III',
    key_data: 'PADOVA: 28% reduction in motor progression in rapidly progressing subgroup; PASADENA: signals in motor function',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First anti-synuclein to show motor benefit', 'Disease modification potential', 'Strong Roche partnership'],
    weaknesses: ['Missed primary endpoint in PASADENA', 'Subgroup-driven benefit', 'Long development timeline'],
    source: 'PADOVA (NCT04777331); Roche/Prothena 2024',
    last_updated: '2024-12-01',
  },

  // ══════════════════════════════════════════════════════════
  // RHEUMATOID ARTHRITIS
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Humira',
    generic_name: 'adalimumab',
    company: 'AbbVie',
    indication: 'Rheumatoid Arthritis',
    indication_specifics: 'Moderate-to-severe RA after csDMARD failure',
    mechanism: 'Anti-TNF monoclonal antibody',
    mechanism_category: 'anti_tnf',
    molecular_target: 'TNF-alpha',
    phase: 'Approved',
    primary_endpoint: 'ACR20',
    key_data: 'ARMADA/PREMIER: ACR20 67-73% at 6 months; > 15 years of real-world data',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Best-selling drug in history', 'Extensive evidence base', 'Multiple autoimmune indications'],
    weaknesses: ['Biosimilar erosion (10+ biosimilars launched)', 'Class infection risk', 'Revenue declining rapidly'],
    source: 'FDA label; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rinvoq',
    generic_name: 'upadacitinib',
    company: 'AbbVie',
    indication: 'Rheumatoid Arthritis',
    indication_specifics: 'Moderate-to-severe RA after csDMARD inadequate response',
    mechanism: 'JAK1 inhibitor (selective)',
    mechanism_category: 'jak_inhibitor',
    molecular_target: 'JAK1',
    phase: 'Approved',
    primary_endpoint: 'ACR20',
    key_data: 'SELECT-COMPARE: ACR50 45.2% vs 29.1% vs Humira at 12 wk; radiographic superiority',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Superior to adalimumab in ACR50', 'Oral convenience', 'Multiple autoimmune indications'],
    weaknesses: ['JAK class boxed warning (CV, thrombotic events)', 'FDA label restrictions post-ORAL Surveillance', 'Regulatory headwinds'],
    source: 'FDA label; SELECT trials; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Olokizumab',
    generic_name: 'olokizumab',
    company: 'R-Pharm/UCB',
    indication: 'Rheumatoid Arthritis',
    indication_specifics: 'Moderate-to-severe RA after csDMARD inadequate response',
    mechanism: 'Anti-IL-6 antibody',
    mechanism_category: 'anti_il6',
    molecular_target: 'IL-6',
    phase: 'Phase 3',
    primary_endpoint: 'ACR20',
    key_data: 'CREDO trials: ACR20 non-inferior to tocilizumab; monthly SC dosing',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Monthly SC dosing convenience', 'Non-inferior to tocilizumab', 'Direct IL-6 targeting'],
    weaknesses: ['Crowded RA market', 'JAK inhibitor competition', 'Not clearly differentiated from Actemra'],
    source: 'CREDO trials; R-Pharm 2024',
    last_updated: '2024-10-01',
  },

  // ══════════════════════════════════════════════════════════
  // ULCERATIVE COLITIS
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Entyvio',
    generic_name: 'vedolizumab',
    company: 'Takeda',
    indication: 'Ulcerative Colitis',
    indication_specifics: 'Moderate-to-severe UC after conventional therapy failure',
    mechanism: 'Anti-alpha4beta7 integrin antibody',
    mechanism_category: 'anti_integrin',
    molecular_target: 'Alpha4beta7',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission',
    key_data: 'GEMINI 1: Clinical remission 41.8% vs 15.9% at 52 wk; gut-selective mechanism',
    line_of_therapy: '2L+',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Gut-selective (safety advantage)', '$5B+ blockbuster', 'SC formulation available'],
    weaknesses: ['Slower onset than anti-TNF', 'Biosimilar competition emerging', 'Not effective in all patients'],
    source: 'FDA label; GEMINI trials; Takeda 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Skyrizi',
    generic_name: 'risankizumab',
    company: 'AbbVie',
    indication: 'Ulcerative Colitis',
    indication_specifics: 'Moderate-to-severe UC after conventional therapy failure',
    mechanism: 'Anti-IL-23 (p19) antibody',
    mechanism_category: 'anti_il23',
    molecular_target: 'IL-23 (p19)',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission',
    key_data: 'COMMAND: Clinical remission 36.6% vs 12.5% at 52 wk; strong endoscopic response',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Clean safety profile', 'Growing IL-23 class evidence', 'Dual IBD indication (UC + Crohn\'s)'],
    weaknesses: ['Later entrant vs Stelara/Entyvio', 'SC only', 'Competitive with guselkumab for share'],
    source: 'FDA label; COMMAND trial; AbbVie 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tremfya',
    generic_name: 'guselkumab',
    company: 'Johnson & Johnson',
    indication: 'Ulcerative Colitis',
    indication_specifics: 'Moderate-to-severe UC (Phase 3 ongoing)',
    mechanism: 'Anti-IL-23 (p19) antibody',
    mechanism_category: 'anti_il23',
    molecular_target: 'IL-23 (p19)',
    phase: 'Phase 3',
    primary_endpoint: 'Clinical remission',
    key_data: 'QUASAR: Phase 3 results pending; strong Phase 2 UC data; approved for psoriasis',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Strong psoriasis franchise', 'IL-23 class momentum', 'Dual targeting with CD64 binding'],
    weaknesses: ['Behind Skyrizi in IBD development', 'Phase 3 results pending', 'Crowded class'],
    source: 'QUASAR trials; J&J 2024',
    last_updated: '2024-10-01',
  },

  // ══════════════════════════════════════════════════════════
  // ATOPIC DERMATITIS
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Dupixent',
    generic_name: 'dupilumab',
    company: 'Sanofi/Regeneron',
    indication: 'Atopic Dermatitis',
    indication_specifics: 'Moderate-to-severe AD in adults and children >= 6 months',
    mechanism: 'Anti-IL-4Ra monoclonal antibody (blocks IL-4 and IL-13)',
    mechanism_category: 'anti_il4',
    molecular_target: 'IL-4Ra',
    phase: 'Approved',
    primary_endpoint: 'EASI-75',
    key_data: 'LIBERTY AD: EASI-75 51% vs 15% at 16 wk; $12B+ blockbuster across indications',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First-in-class biologic in AD', 'Pediatric approval', '$12B+ revenue across indications'],
    weaknesses: ['Injection site reactions', 'Conjunctivitis', 'JAK inhibitor competition'],
    source: 'FDA label; LIBERTY AD trials; Sanofi 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Adbry',
    generic_name: 'tralokinumab',
    company: 'LEO Pharma',
    indication: 'Atopic Dermatitis',
    indication_specifics: 'Moderate-to-severe AD in adults',
    mechanism: 'Anti-IL-13 monoclonal antibody',
    mechanism_category: 'anti_il13',
    molecular_target: 'IL-13',
    phase: 'Approved',
    primary_endpoint: 'EASI-75',
    key_data: 'ECZTRA 1/2: EASI-75 25-33% monotherapy at 16 wk; improved with TCS',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Selective IL-13 targeting', 'Good safety profile', 'Alternative for Dupixent non-responders'],
    weaknesses: ['Lower efficacy than Dupixent', 'Limited market share', 'No pediatric indication yet'],
    source: 'FDA label; ECZTRA trials; LEO Pharma 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cibinqo',
    generic_name: 'abrocitinib',
    company: 'Pfizer',
    indication: 'Atopic Dermatitis',
    indication_specifics: 'Moderate-to-severe AD in adults after other systemics',
    mechanism: 'JAK1 inhibitor (oral)',
    mechanism_category: 'jak_inhibitor',
    molecular_target: 'JAK1',
    phase: 'Approved',
    primary_endpoint: 'IGA 0/1',
    key_data: 'JADE COMPARE: 200mg IGA 0/1 48.4% vs 36.5% dupilumab vs 14.0% placebo at 12 wk',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Oral convenience', 'Rapid onset of action', 'Numerical superiority vs Dupixent at high dose'],
    weaknesses: ['JAK boxed warning', 'Restricted to after other systemics', 'Herpes zoster risk'],
    source: 'FDA label; JADE trials; Pfizer 2024',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // SPINAL MUSCULAR ATROPHY (SMA) — Rare Disease
  // ══════════════════════════════════════════════════════════

  {
    asset_name: 'Zolgensma',
    generic_name: 'onasemnogene abeparvovec',
    company: 'Novartis',
    indication: 'Spinal Muscular Atrophy',
    indication_specifics: 'SMA Type 1 in patients < 2 years',
    mechanism: 'AAV9 gene therapy (SMN1 gene replacement)',
    mechanism_category: 'gene_therapy',
    molecular_target: 'SMN1',
    phase: 'Approved',
    primary_endpoint: 'Survival/motor milestones',
    key_data: 'STR1VE: 91% survived event-free at 14 mo; 59% sitting independently',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['One-time curative therapy', 'Dramatic motor milestone achievement', 'Transformative for SMA Type 1'],
    weaknesses: ['$2.1M price point', 'Hepatotoxicity (TMA)', 'Age/weight restrictions', 'Immunogenicity to AAV9'],
    source: 'FDA label; STR1VE trial; Novartis 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Spinraza',
    generic_name: 'nusinersen',
    company: 'Biogen',
    indication: 'Spinal Muscular Atrophy',
    indication_specifics: 'All types of SMA (intrathecal administration)',
    mechanism: 'Antisense oligonucleotide (SMN2 splicing modifier)',
    mechanism_category: 'antisense_oligonucleotide',
    molecular_target: 'SMN2',
    phase: 'Approved',
    primary_endpoint: 'Motor function (HFMSE)',
    key_data: 'ENDEAR: 51% motor milestone responders vs 0% in SMA Type 1; NURTURE: presymptomatic benefit',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['First SMA therapy approved', 'Broadest age/type coverage', 'Long-term safety data'],
    weaknesses: ['Intrathecal administration every 4 months', 'Declining revenue with Zolgensma/Evrysdi competition', 'Access challenges for older patients'],
    source: 'FDA label; ENDEAR/NURTURE trials; Biogen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Evrysdi',
    generic_name: 'risdiplam',
    company: 'Roche/Genentech',
    indication: 'Spinal Muscular Atrophy',
    indication_specifics: 'All types of SMA, age >= 2 months (oral)',
    mechanism: 'Small molecule SMN2 splicing modifier',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'SMN2',
    phase: 'Approved',
    primary_endpoint: 'Motor function',
    key_data: 'FIREFISH: Type 1 sitting 29% at 12 mo; SUNFISH: Type 2/3 MFM-32 improvement',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: ['Oral (liquid) at-home dosing', 'No age restriction above 2 months', 'CNS + peripheral distribution'],
    weaknesses: ['Requires continuous daily dosing', 'Lower efficacy ceiling than Zolgensma in Type 1', 'Retinal toxicity signal in animals'],
    source: 'FDA label; FIREFISH/SUNFISH trials; Roche 2024',
    last_updated: '2025-01-15',
  },
];

// ────────────────────────────────────────────────────────────
// QUERY HELPERS
// ────────────────────────────────────────────────────────────

/**
 * Returns all competitors for a given indication name.
 * Uses case-insensitive partial matching to handle synonyms and abbreviations.
 */
export function getCompetitorsForIndication(indicationName: string): CompetitorRecord[] {
  const normalized = indicationName.toLowerCase().trim();
  return COMPETITOR_DATABASE.filter(c =>
    c.indication.toLowerCase() === normalized ||
    c.indication.toLowerCase().includes(normalized) ||
    normalized.includes(c.indication.toLowerCase())
  );
}

/**
 * Returns a deduplicated list of mechanism categories present
 * among a set of competitor records.
 */
export function getUniqueMechanisms(competitors: CompetitorRecord[]): string[] {
  return Array.from(new Set(competitors.map(c => c.mechanism_category)));
}

/**
 * Returns competitors filtered by mechanism category.
 */
export function getCompetitorsByMechanism(mechanism: string): CompetitorRecord[] {
  const normalized = mechanism.toLowerCase().trim();
  return COMPETITOR_DATABASE.filter(c =>
    c.mechanism_category.toLowerCase() === normalized ||
    c.mechanism.toLowerCase().includes(normalized)
  );
}

/**
 * Returns competitors at a specific clinical phase.
 */
export function getCompetitorsByPhase(phase: ClinicalPhase): CompetitorRecord[] {
  return COMPETITOR_DATABASE.filter(c => c.phase === phase);
}
